February 24, 2025 10:37 AM ESTUpdated 11:04 AM
News Briefing

FDA won’t al­low In­vivyd’s Pem­gar­da to treat Covid; An­tibi­ot­ic biotech launch­es

ENDPOINTS

Plus, news about BioCryst, AN2 Ther­a­peu­tics, OS Ther­a­pies and Eye­n­ovia:

FDA is not ex­pand­ing In­vivyd’s Covid-19 EUA: The reg­u­la­tors de­clined to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Mile­stone's shares dive af­ter FDA again re­jects drug for ab­nor­mal heart rhythm

A service from the Financial Times